DSIP (nonapeptide): the complete research guide.

No peptide in our library has a bigger gap between marketing and evidence than DSIP. It's a 9-amino-acid sequence isolated almost 50 years ago. Sellers still call it a sleep peptide. The published research has quietly walked away from that claim.

DSIP's story is one of the longest unresolved questions in sleep neuroscience. In 1977, two Swiss researchers named Schoenenberger and Monnier drew blood from rabbits whose brains had been electrically pushed into deep sleep.

They isolated a peptide they believed triggered the sleep and called it the delta sleep-inducing peptide. Their hypothesis was that they'd found the body's missing sleep signal.

Fifty years later, we're still calling it a hypothesis. No DSIP receptor has been identified. No clear role in mammalian sleep has been proven. The molecule does cross the blood-brain barrier, but poorly. It does have measurable effects in some lab tests. But the original claim — that DSIP is the body's natural sleep signal — has never been confirmed.

And yet we keep seeing DSIP marketed as a sleep peptide. The marketing leans on the 1977 paper and the name. The Western randomized-trial evidence base, as of 2026, is empty.

What is DSIP, structurally?

DSIP is a 9-amino-acid peptide. The sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). It has no chemical modifications, no cyclic structure, and no unusual amino acids. It dissolves easily in water. By peptide-pharmacology standards, the molecule is unremarkable.

The structural fact that matters most is that DSIP crosses the blood-brain barrier poorly. Researchers have known this for decades, and it governs how you should read any claim about DSIP acting on the brain.

Recent Russian and Chinese work uses engineered fusion peptides built to get around the barrier. That design choice is itself an admission: plain DSIP doesn't reach the brain in useful amounts.

The original 1977 isolation came from dialyzing rabbit brain blood. The active fraction was a 75 ng/mL peptide that, when injected into other rabbits, increased deep (delta) sleep. The method was novel for 1977. The finding was striking. But replication has been spotty, and the field has spent five decades unable to find what receptor DSIP binds.

What does the modern research actually study?

We read the 2020 to 2025 DSIP literature, and one thing stands out. The most rigorous work isn't on sleep. It's on protecting brains and hearts from stroke and heart-attack damage. The Shemyakin-Ovchinnikov Institute in Moscow has the most active program, and its focus has shifted decisively to injury protection.

Tukhovskaya and colleagues published a 2021 study on intranasal DSIP and a tweaked analog called KND peptide. Both reduced stroke and heart-attack damage in rodents when given during reperfusion, the moment blood flow returns to damaged tissue.

The KND analog beat plain DSIP on some endpoints. That suggests fixing the blood-brain barrier problem does improve the signal.

The most important safety finding in the modern DSIP literature is buried in that paper's methods section. In pilot work before the main experiments, the team gave the peptide during the stroke itself instead of after. Every animal died. 100% mortality. That's not a footnote. That's a warning about timing.

That timing-dependent toxicity signal matters, because DSIP is widely used in grey-market channels. FDA-approved sleep medications carry characterized dose ranges, known adverse-event profiles and documented worst-case data.

You won't find the 100% mortality result in grey-market product descriptions of DSIP. We think that omission is the most telling thing about how this compound gets sold.

A separate 2021 Tukhovskaya paper reported that intranasal DSIP at 120 mcg/kg for 7 days after stroke improved rats' motor coordination on a rotarod test.

It didn't shrink the stroke damage itself. That's the closest modern Russian work has come to a clean neuroprotective finding, and even there the effect is on function, not tissue.

DSIP

Nonapeptide 9 aa Endogenous

The same compound cited across the modern preclinical studies in this review. Lab-verified identity and purity.

Shop DSIP

What does the recent sleep work show?

The closest recent study to DSIP's original purpose is a 2024 paper from Mu and colleagues in Frontiers in Pharmacology. They built a fusion peptide combining DSIP with a blood-brain-barrier-crossing tag.

They tested it in a mouse insomnia model induced by PCPA, a drug that depletes serotonin and wrecks sleep.

The fusion peptide nudged 4 neurotransmitters back toward normal in the insomnia model: serotonin, glutamate, dopamine and melatonin. The authors reported a "better restorative effect than DSIP" on neurotransmitter balance.

Two things stand out. It's a serious modern attempt to test a DSIP-based intervention in a sleep-relevant model. And the authors openly say that plain DSIP works less well than the barrier-engineered version.

That matches our long-standing concern. Plain DSIP doesn't reach the brain in useful amounts.

The methodological implication is significant. The closest recent sleep-relevant study validates a different molecule — a fusion peptide. Plain DSIP is the version the same paper identifies as performing worse on neurotransmitter endpoints. The mechanistic case for plain DSIP as a sleep-relevant research compound therefore rests substantially on the 1977 foundational paper.

Why has the mechanism never been pinned down?

This is the unresolved question of the entire DSIP literature. Researchers have tried many angles over the decades. None has produced a definitive DSIP receptor or a validated mechanism for sleep induction.

Candidate mechanisms in the recent literature include effects on 4+ neurotransmitter systems, meaning serotonin, glutamate, dopamine and melatonin in the 2024 Mu paper. The list also holds possible stress-axis effects, antioxidant activity and broad neuroprotection in stroke models.

Not one of them explains the sleep effect reported in 1977.

Our current assessment is this. DSIP looks like a biologically active peptide with several small, scattered effects across neurotransmitter systems.

None of them add up to "sleep induction" the way the 1977 model proposed. The molecule is real and measurably active in some assays. Whether those activities explain the original observation is still open after 50 years.

What human evidence exists?

Almost none, in any indication. Despite DSIP's 50-year history, there's zero contemporary randomized controlled trials documenting that exogenous DSIP works in humans for sleep, stress, or anything else.

That's unusual. Most research peptides with multi-decade histories have at least one small pilot human study on PubMed, even a flawed one. DSIP doesn't.

Russian-language clinical work on DSIP does exist in the historical record. It isn't Western-RCT-grade, it isn't PubMed-indexed in the modern sense, and it predates current methodology standards for sleep trials.

The claims we keep seeing in marketing copy rest on three things. The 1977 paper. A thin layer of Russian preclinical work that has moved away from sleep. And zero modern human RCT evidence.

What about safety?

Modern human safety data for DSIP is essentially absent. The Russian preclinical work flagged one timing-dependent toxicity signal: a 100% animal death rate with mistimed stroke-model dosing.

That's worth sitting with, given the dominant grey-market use is undirected evening dosing in healthy people.

Other safety considerations remain theoretical and untested. DSIP's effects on neurotransmitter systems raise plausible interaction concerns with antidepressants, antipsychotics, opioids, and sedatives. Modulation of the HPA stress axis raises theoretical considerations in the context of corticosteroid co-administration. None of these interactions has been formally characterized in published clinical data.

Long-term safety of repeated DSIP administration remains entirely unstudied — not because the signal is reassuring, but because no longitudinal trials have been conducted. Modern clinical safety data for chronic administration does not exist in the published literature.

What's the regulatory status?

Unapproved everywhere that matters. The FDA, the EMA and every other major Western regulator have approved DSIP for nothing.

It has a Russian preclinical history but no broadly recognized therapeutic approval in Russia either. Selank and Semax, by contrast, do carry approved Russian indications.

DSIP isn't explicitly named on the WADA Prohibited List. If you compete, verify that with your governing body rather than taking it from us. In the US the compound is sold in the grey market as a research peptide.

DSIP

5 mg ≥99% pure Lyophilized

Nonapeptide · 9 aa, endogenous sequence. The same reference compound used across the cited preclinical studies. COA available with each lot.

Learn more

Evaluating DSIP against the current evidence base

Held against contemporary evidence standards, the case for plain DSIP as a sleep intervention is essentially unsupported. The founding sleep-induction claim is still unconfirmed after 50 years.

Modern research programs have moved to stroke and cardiac reperfusion injury. A timing-dependent safety signal sits in the preclinical literature, and no Western RCT has run in any indication.

Poor blood-brain barrier penetration is acknowledged in the recent publications themselves, which is why they've moved to engineered fusion variants.

If you're placing DSIP in the wider sleep-intervention landscape, the comparison isn't close. CBT-I for chronic insomnia, validated melatonin formulations and characterized hypnotics each carry far more human trial evidence than DSIP does in any indication.

Key open questions in the literature include the following.

• Adequacy of the 1977 foundational study. The Schoenenberger and Monnier isolation represents the evidentiary foundation. The methodological standards of 1977 differ substantially from current RCT requirements for sleep endpoints.
• Timing-dependent toxicity in preclinical models. The 100% animal mortality observed with mistimed stroke-model administration (Tukhovskaya et al., 2021) represents the most consequential safety signal in the modern literature.
• Blood-brain barrier penetration of plain DSIP. Recent research programs have shifted to engineered fusion variants precisely because plain DSIP does not cross the barrier with sufficient efficiency — a point acknowledged in the primary literature.
• Absence of human pharmacokinetic data. No contemporary PK/PD studies for plain DSIP in human research subjects have been published in PubMed-indexed journals.